文献速递类风湿关节炎

达标治疗干预对类风湿关节炎患者心血管风险因素及亚临床与临床动脉粥样硬化的影响:一项随机临床试验

Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial.
PubMed 文献 · Ann Rheum Dis · 2019-01-04

本研究为开放标签随机对照试验,纳入320例无既往心血管疾病或糖尿病的类风湿关节炎患者,1:1随机接受传统心血管风险因素达标治疗或常规护理。主要结局为5年颈动脉内膜中层厚度变化,达标治疗组平均进展显著低于常规护理组(0.023 mm vs 0.045 mm,p=0.028),心血管事件发生率亦较低(1.3% vs 4.7%,p=0.048)。

要点

  • 达标治疗可显著减缓类风湿关节炎患者5年颈动脉内膜中层厚度进展。
  • 达标治疗组心血管事件发生率低于常规护理组(1.3% vs 4.7%,p=0.048)。
  • 研究支持对病情控制良好的类风湿关节炎患者进行传统心血管风险因素达标管理以助一级预防。

核心结论

  • 对病情控制良好的类风湿关节炎患者,传统心血管风险因素达标治疗策略有助于心血管疾病一级预防。

研究设计与样本

  • 开放标签随机对照试验,纳入320例年龄<70岁、无既往心血管疾病或糖尿病的类风湿关节炎患者,1:1随机分为达标治疗组或常规护理组。
  • 219例(68.4%)完成5年随访;主要结局为5年颈动脉内膜中层厚度变化,次要结局为致命和非致命心血管事件的复合终点。

主要发现

  • 达标治疗组平均颈动脉内膜中层厚度进展为0.023 mm(95%CI 0.011至0.036),常规护理组为0.045 mm(95%CI 0.030至0.059),组间差异显著(p=0.028)。
  • 达标治疗组心血管事件发生2例(1.3%),常规护理组发生7例(4.7%),log-rank检验p=0.048。

临床怎么用

  • 在类风湿关节炎患者中,可考虑对传统心血管风险因素采用达标治疗策略以延缓亚临床动脉粥样硬化进展并减少心血管事件。

局限性

  • 本研究为开放标签设计,非盲法可能引入偏倚。
  • 完成5年随访的患者比例为68.4%,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular disease (CVD). No long-term intervention trials on CVD risk factors have been published, and a debate on the efficacy of controlling traditional risk factors in RA is ongoing. We aimed to evaluate a treat-to-target approach versus usual care regarding traditional CVD risk factors in patients with RA. METHODS: In this open-label, randomised controlled trial, patients with RA aged <70 years without prior CVD or diabetes mellitus were randomised 1:1 to either a treat-to-target approach or usual care of traditional CVD risk factors. The primary outcome was defined as change in carotid intima media thickness (cIMT) over 5 years, and the secondary outcome was a composite of first occurrence of fatal and non-fatal cardiovascular events. RESULTS: A total of 320 patients (mean age 52.4 years; 69.7% female) with RA underwent randomisation and 219 patients (68.4%) completed 5 years of follow-up. The mean cIMT progression was significantly reduced in the treat-to-target group compared with usual care (0.023 [95% CI 0.011 to 0.036] mm vs 0.045 [95% CI 0.030 to 0.059] mm; p=0.028). Cardiovascular events occurred in 2 (1.3%) of the patients in the treat-to-target group vs 7 (4.7%) in those receiving usual care (p=0.048 by log-rank test). CONCLUSION: This study provides evidence on the benefit of a treat-to-target approach of traditional CVD risk factors for primary prevention in patients with well-treated RA. TRIAL REGISTRATION NUMBER: NTR3873.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Burggraaf B, van Breukelen-van der Stoep DF, de Vries MA, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2019. PMID: 30610067. doi:10.1136/annrheumdis-2018-214075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。